First Drug to Delay Type 1 Diabetes Now Free on NHS

Hundreds of children will soon gain three extra years of childhood free from the daily demands of type 1 diabetes, thanks to a revolutionary drug now available on the NHS.

Teplizumab became the first treatment approved in England and Wales that can delay the onset of type 1 diabetes symptoms. The immunotherapy works by stopping the immune system from attacking insulin-producing cells in the pancreas, giving young patients more time before they need lifelong insulin treatment.

For families like the Sebastian-Jenkins, this news arrives with bittersweet hope. Their son Theo was diagnosed at four, too young to qualify for the treatment, which starts at age eight. Now his parents watch him navigate daily blood sugar checks, careful meal planning, and the constant worry that comes with the condition.

"It would be huge for any family to have those three years of childhood back without the worry," says Theo's dad Ben. Every meal requires weighing food and calculating carbohydrates to determine the right insulin dose. If blood sugar drops too low, it becomes a medical emergency.

The treatment requires 14 consecutive days of hospital infusions, a grueling process that nine-year-old Dima Boichak completed as one of the first recipients. His mother Elena discovered his risk through a research study after his cousin was diagnosed.

"The biggest gift teplizumab gives us is time, just time being a normal kid, living a normal life," Elena says. Despite the challenging two-week process, she believes those extra years are worth it.

The Ripple Effect

This breakthrough represents decades of work by researchers and diabetes charities who never stopped believing a preventive treatment was possible. Around 1,100 adults and children could receive the drug in its first year, with 820 patients annually after initial demand is met.

The approval signals something even bigger on the horizon. Multiple type 1 diabetes immunotherapy treatments are now in development, raising hopes that future patients might receive personalized combinations of drugs that could prevent the disease entirely.

Karen Addington, chief executive of charity Breakthrough T1D, calls the impact "momentous." Her organization funded the early research that made teplizumab possible, investing in a future where parents might not hear those devastating words: your child has type 1 diabetes.

The NHS negotiated a confidential discount from the £150,000 list price, making the treatment accessible to families who need it most. Helen Knight from NICE called it "genuinely exciting" that people can now gain precious extra time before managing the full demands of the condition.

For now, patients must first get a blood test showing their immune system has begun attacking the pancreas. Diabetes charities are campaigning for routine screening programs like the one already established in Italy, which could identify at-risk children earlier and give more families the gift of time.